{"id":91367,"date":"2026-05-19T12:13:24","date_gmt":"2026-05-19T06:43:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=91367"},"modified":"2026-05-19T12:13:25","modified_gmt":"2026-05-19T06:43:25","slug":"goldline-pharmaceutical-share-price-5-percent-lower-circuit-after-listing","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-share-price-5-percent-lower-circuit-after-listing\/","title":{"rendered":"Goldline Pharmaceutical Share Price Locked in 5% Lower Circuit After Bumper BSE SME Debut: Rs 59.87 Open, Rs 56.66 Circuit \u2014 What Happened and What Next"},"content":{"rendered":"

The Goldline Pharmaceutical share price<\/strong> delivered a sharp and dramatic post-listing narrative on 19 May 2026. The stock opened at Rs 59.87 on BSE SME at 9:40 AM \u2014 a 39.2 percent premium over the Rs 43 issue price \u2014 confirming the pre-listing grey market premium estimate. However, within two hours, the Goldline Pharmaceutical share price was locked in a 5 percent lower circuit at approximately Rs 56.66 to Rs 56.77, where it remained flat for the rest of the trading session, up 32.02 percent from the issue price.<\/p>

The pattern played out almost exactly as pre-listing analysis had predicted: the 1,662 times oversubscribed NII (HNI) category flooded the market with selling as thousands of investors who had received tiny proportionate allotments (some as little as 5 shares) rushed to sell at the opening price, creating a sharp downward pressure that sent the Goldline Pharmaceutical share price from its Rs 59.87 peak to the lower circuit.<\/p>

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n